title: Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1.
abstract: OBJECTIVE
  We examined metabolic changes in the period immediately after the diagnosis of type 1 diabetes and in the period leading up to its diagnosis in Diabetes Prevention Trial-Type 1 (DPT-1) participants.
  
  
  METHODS
  The study included oral insulin trial participants and parenteral insulin trial control subjects (n = 63) in whom diabetes was diagnosed by a 2-h diabetic oral glucose tolerance test (OGTT) that was confirmed by another diabetic OGTT within 3 months. Differences in glucose and C-peptide levels between the OGTTs were assessed.
  
  
  RESULTS
  Glucose levels increased at 90 (P = 0.006) and 120 min (P < 0.001) from the initial diabetic OGTT to the confirmatory diabetic OGTT (mean +/- SD interval 5.5 +/- 2.8 weeks). Peak C-peptide levels fell substantially between the OGTTs (median change -14.3%, P < 0.001). Among the 55 individuals whose last nondiabetic OGTT was approximately 6 months before the initial diabetic OGTT, peak C-peptide levels decreased between these two OGTTs (median change -14.0%, P = 0.052). Among those same individuals the median change in peak C-peptide levels from the last normal OGTT to the confirmatory OGTT (interval 7.5 +/- 1.3 months) was -23.8% (P < 0.001). Median rates of change in peak C-peptide levels were 0.00 ng x ml(-1) x month(-1) (P = 0.468, n = 36) from approximately 12 to 6 months before diagnosis, -0.10 ng x ml(-1) x month(-1) (P = 0.059, n = 55) from 6 months before diagnosis to diagnosis, and -0.43 ng x ml(-1) x month(-1) (P = 0.002, n = 63) from the initial diabetic OGTT to the confirmatory diabetic OGTT.
  
  
  CONCLUSIONS
  It seems that postchallenge C-peptide levels begin to decrease appreciably in the 6 months before diagnosis and decrease even more rapidly within 3 months after diagnosis.
authors.affiliation: Division of Endocrinology, University of Miami, Miami, Florida, USA. jsosenko@med.miami.edu
authors.forename: Jay M
authors.initials: JM
authors.lastname: Sosenko
authors.forename: Jerry P
authors.initials: JP
authors.lastname: Palmer
authors.forename: Lisa
authors.initials: L
authors.lastname: Rafkin-Mervis
authors.forename: Jeffrey P
authors.initials: JP
authors.lastname: Krischer
authors.forename: David
authors.initials: D
authors.lastname: Cuthbertson
authors.forename: Della
authors.initials: D
authors.lastname: Matheson
authors.forename: Jay S
authors.initials: JS
authors.lastname: Skyler
mesh_terms: D001786:Blood Glucose / Q000378:metabolism*; D002096:C-Peptide / Q000097:blood*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000378:metabolism / Q000517:prevention & control; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D008297:Male; D011236:Prediabetic State / Q000097:blood* / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D002096:C-Peptide